This rapid expert consultation focuses on monoclonal antibody (mAbs) therapies authorized for use in patients infected with SARS-CoV-2. This consultation describes the approaches taken in different jurisdictions at the federal, state, and local/institutional levels to ensure an effective, equitable, and fair allocation of mAbs and points to challenges in reaching underserved patients.
The National Academies of Sciences, Engineering, and Medicine convened a standing committee of experts to help inform the Office of Science and Technology Policy on critical science and policy issues related to emerging infectious diseases and other public health threats. The standing committee includes members with expertise in emerging infectious diseases, public health, public health preparedness and response, biological sciences, clinical care and crisis standards of care, risk communication, and regulatory issues.
Table of Contents
|Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021)||1-34|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021)...